GRAIL anticipates early Q1 2027 FDA decision while updating 2026 Galleri revenue growth to 17%-21%

• Joshua Ofman (CEO & Director) said the quarter included “a favorable vote for approval from the FDA's Advisory Committee” and journal publications of “NHS-Galleri and PATHFINDER-2 results,” adding that the company “expect[s] to receive a final decision by early Q1

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.